Loading...

Kymera Therapeutics, Inc.

KYMR•NASDAQ
Healthcare
Biotechnology
$84.91
$-2.26(-2.59%)
U.S. Market opens in 49h 27m

Kymera Therapeutics, Inc. (KYMR) Stock Overview

Explore Kymera Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap6.9B
P/E Ratio-23.21
EPS (TTM)$-3.69
ROE-0.29%
Fundamental Analysis

AI Price Forecasts

1 Month$73.26
3 Months$92.40
1 Year Target$80.16

KYMR Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Kymera Therapeutics, Inc. (KYMR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 48.67, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $80.16.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -23.21 and a market capitalization of 6.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-2.59%
5-Day Change
-3.24%
1-Month Change
14.10%
3-Month Change
21.42%
6-Month Change
45.00%
Year-to-Date (YTD) Change
9.12%
1-Year Change
153.010%
3-Year Change
156.60%
5-Year Change
105.29%
All-Time (Max) Change
155.29%

Contact Information

https://www.kymeratx.com
857 285 5300
200 Arsenal Yards Boulevard, Watertown, MA, 02472

Company Facts

208 Employees
IPO DateAug 21, 2020
CountryUS
Actively Trading

Frequently Asked Questions